STOCK TITAN

Eyepoint Pharmac Stock Price, News & Analysis

EYPT Nasdaq

Welcome to our dedicated page for Eyepoint Pharmac news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on Eyepoint Pharmac stock.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical innovator advancing sustained-release therapies for retinal diseases through its proprietary Durasert E technology. This page provides investors and industry professionals with a comprehensive repository of official company news, including press releases, clinical trial updates, and strategic developments.

Access timely updates on EYPT’s progress in ocular drug delivery, including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures you stay informed about critical developments in treatments for wet AMD, diabetic macular edema, and other retinal conditions.

Key updates include progress on DURAVYU™ clinical trials, licensing agreements, financial disclosures, and scientific innovations. All content is sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to EyePoint’s latest developments. Check back regularly for authoritative updates on one of ophthalmology’s most promising sustained-release therapy developers.

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:30 am ET. The event will be accessible via a live webcast and an archived replay on the Investors section of the Company's website, available for 90 days post-event. EyePoint specializes in therapeutics for serious eye disorders, notably using its Durasert® technology for sustained drug delivery, with products like YUTIQ® and the pipeline candidate EYP-1901 targeting wet age-related macular degeneration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to four new employees, totaling 56,500 shares. These options, approved by the Compensation Committee, were granted on April 14, 2022, with an exercise price of $12.69 per share. The awards aim to incentivize employment and have a ten-year term, vesting over four years, with 25% vesting after one year and the rest in monthly installments. EyePoint focuses on developing therapeutics for serious eye disorders, leveraging its Durasert technology for drug delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none
-
Rhea-AI Summary

On March 15, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted non-statutory stock options to six new employees as inducement awards outside its 2016 Long-Term Incentive Plan. A total of 6,250 options were issued, each with an exercise price of $12.05, reflecting the closing stock price on the grant date. The options have a ten-year term, vesting 25% on the first anniversary and the remaining monthly over three years, contingent on continued employment. This move aims to attract talent to enhance its pipeline, including the Durasert®-based treatment for serious eye disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.55%
Tags
none
Rhea-AI Summary

EyePoint Pharmaceuticals has secured a $45 million loan agreement with Silicon Valley Bank, replacing its previous credit facility. This new arrangement lowers the interest rate from 12.5% to approximately 5%, leading to annualized savings of about $2.8 million. It comprises a $30 million term loan and a revolving credit facility of up to $15 million, primarily backed by the company’s accounts receivable. As of December 31, 2021, EyePoint had $211.6 million in cash and investments, enhancing its financial stability for future developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
none
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer, succeeding John Weet. With over 30 years of experience in regulatory affairs, Lefebvre previously led regulatory strategy at Hengrui USA and has a strong background in ocular drug approvals from her time at Bausch Health. Her expertise is seen as critical in advancing EyePoint's pipeline, particularly EYP-1901, aimed at treating retinal diseases. The company also granted her stock options for entering employment, compliant with Nasdaq rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
management
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported significant financial growth for 2021, with net product revenues increasing by 70% to $35.3 million compared to $20.8 million in 2020. The company also highlighted positive eight-month data from the Phase 1 DAVIO trial of EYP-1901 for wet AMD, with Phase 2 trials expected to commence in Q3 2022. However, the company also reported a net loss of $58.4 million, up from $45.4 million the previous year, attributed to increased operating expenses. Cash reserves reached $211.6 million, providing operational funding into late 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 10:30 a.m. ET. This presentation will highlight the company's commitment to developing innovative therapeutics for serious eye disorders. Investors can access a live webcast and an archived replay through the company website for 90 days post-event. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, utilizing its Durasert® technology for sustained drug delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 3, 2022, at 8:30 a.m. ET, to discuss its Q4 and full-year 2021 financial results and corporate developments. Interested participants can join by calling (877) 312-7507 domestically or (631) 813-4828 internationally, using conference ID 5058194. This presentation will also be available via live audio webcast on the company's website, with a replay accessible post-event. EyePoint is focused on therapeutics to treat serious eye disorders, leveraging its Durasert® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences earnings
-
Rhea-AI Summary

EyePoint Pharmaceuticals (EYPT) announced positive interim data from the Phase 1 DAVIO clinical trial of EYP-1901, an intravitreal anti-VEGF treatment for wet age-related macular degeneration (AMD). The results, presented by Dr. Jay Duker, indicate a strong safety profile with no serious adverse events reported. After eight months, 41% of patients did not need supplemental anti-VEGF injections, showcasing a significant 75% reduction in treatment burden. A Phase 2 trial is anticipated in Q3 2022, following FDA discussions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has released updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD, demonstrating positive safety and efficacy over eight months. A Phase 2 study is set to begin in Q3 2022 following a productive meeting with the FDA. In Q4 2021, customer demand for YUTIQ® and DEXYCU® surged by 16% and 5%, with cash reserves of approximately $210 million. Additionally, the company appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, reinforcing its leadership as it pivots to retina-focused treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
none

FAQ

What is the current stock price of Eyepoint Pharmac (EYPT)?

The current stock price of Eyepoint Pharmac (EYPT) is $5.81 as of May 9, 2025.

What is the market cap of Eyepoint Pharmac (EYPT)?

The market cap of Eyepoint Pharmac (EYPT) is approximately 502.3M.
Eyepoint Pharmac

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

502.32M
63.43M
1.13%
109.64%
15.62%
Biotechnology
Laboratory Analytical Instruments
Link
United States
WATERTOWN